Bat-19 Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)

Secondary Activities: Pharmaceutical Preparation Manufacturing | Medical Equipment and Supplies Manufacturing | Computer and Computer Peripheral Equipment and Software Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Pharmacies and Drug Stores | Other Publishers | Computer Systems Design and Related Services

Full name: Bat-19 Sp. z o.o.

Profile Updated: April 14, 2026

Bat-19 Sp. z o.o. is an enterprise located in Poland, with the main office in Warsaw. It operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. The enterprise was incorporated on January 13, 2023. Its’ total assets recorded a negative growth of 71.15%.

Headquarters
Ul. Aleja Solidarnosci 68/121
Warsaw; Mazowieckie; Postal Code: 00-240

Contact Details: Purchase the Bat-19 Sp. z o.o. report to view the information.

Basic Information

Registered Capital:

Purchase the Bat-19 Sp. z o.o. report to view the information.

Financial Auditors:

Purchase the Bat-19 Sp. z o.o. report to view the information.

Incorporation Date:

January 13, 2023

Key Executives

Purchase this report to view the information.

President

Ownership Details

Purchase this report to view the information.

95%

Company Performance

Financial values in the chart are available after Bat-19 Sp. z o.o. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Total Operating Revenue

-100%▼

Operating Profit

88.62%▲

EBITDA

88.62%▲

Net Profit/Loss for the Period

88.16%▲

Total Assets

-71.15%▼

Total Equity

-13.88%▼

Return on Equity (ROE)

-105.03%▼

Debt / Equity

96.87%▲

Quick Ratio

-0.32%▼

Similar companies